Skip to main content
. 2018 Feb 6;9(76):34200–34212. doi: 10.18632/oncotarget.24409

Figure 6. Carnosol attenuates gastric cancer patient-derived xenograft tumor growth in vivo.

Figure 6

Mice were divided into 2 groups to assess the effect of carnosol on gastric cancer patient-derived xenograft. Groups are as follows: 1) vehicle group or 2) administration of 100 mg/kg of carnosol. Mice were orally administered carnosol or vehicle 5 times a week for 18 days. (A–B) Carnosol inhibits gastric tumor growth. For (A–B), data are shown as means ± S.E. of values obtained from experiments. The asterisk (*) indicates a significant difference between tumors from untreated or treated mice as determined by t test (p < 0.05). (C) Immunohistochemistry analysis of tumor tissues. Tumor tissues from treated or untreated groups of mice were stained with anti-Ki-67. The number of Ki-67-positive stained cells (right panel) was quantified from immunohistochemistry results (n = 10; *; p < 0.05). (D) Carnosol inhibits RSK-mediated CREB signaling protein expression in gastric tumor tissues. Tumor tissues from each group were immunoblotted with antibodies to detect RSKs, CREB, phosphorylated RSKs, phosphorylated CREB and β-actin. β-Actin was used to verify equal protein loading. Band density was measured using the Image J (NIH) software program.